132 related articles for article (PubMed ID: 1293167)
1. 5-S-cysteinyldopa in urine and tumors.
Hara H; Chino K; Kawanami T; Sameshima T; Morishima T
J Dermatol; 1992 Nov; 19(11):806-8. PubMed ID: 1293167
[TBL] [Abstract][Full Text] [Related]
2. [Biochemical diagnoses of malignant melanomas with determinations of 5-S-cysteinyldopa in lesions].
Sameshima T; Morishima T
Nihon Hifuka Gakkai Zasshi; 1989 May; 99(6):665-72. PubMed ID: 2511358
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the clinical usefulness of measuring urinary excretion of 5-S-cysteinyldopa in melanoma: ten years' experience of 50 patients.
Sasaki Y; Shimizu H; Naka W; Takeshita E; Nishikawa T
Acta Derm Venereol; 1997 Sep; 77(5):379-81. PubMed ID: 9298132
[TBL] [Abstract][Full Text] [Related]
4. Serum 5-S-cysteinyldopa (5-S-CD) as a marker of melanoma progression.
Horikoshi T; Ito S
J Dermatol; 1992 Nov; 19(11):809-13. PubMed ID: 1293168
[TBL] [Abstract][Full Text] [Related]
5. Cysteinyldopa isomers and dopa in lesions and urine of Japanese patients with malignant melanoma.
Morishima T; Tatsumi F; Fukada E; Saito M; Fujita M; Nagashima N; Hanawa S
Arch Dermatol Res; 1983; 275(2):76-9. PubMed ID: 6409012
[TBL] [Abstract][Full Text] [Related]
6. [5-S-cysteinyldopa in the urine - a "tumor test" for malignant melanoma? Comparison with the usual laboratory examinations].
Paul E; Graef V; Ruppel R
Z Hautkr; 1980 Dec; 55(23):1543-60. PubMed ID: 6782780
[TBL] [Abstract][Full Text] [Related]
7. 5 years' experience of 5-S-cysteinyldopa in melanoma diagnosis.
Agrup G; Agrup P; Andersson T; Hafström L; Hansson C; Jacobsson S; Jönsson PE; Rorsman H; Rosengren AM; Rosengren E
Acta Derm Venereol; 1979; 59(5):381-8. PubMed ID: 93360
[TBL] [Abstract][Full Text] [Related]
8. S100B protein, 5-S-cysteinyldopa and 6-hydroxy-5-methoxyindole-2-carboxylic acid as biochemical markers for survival prognosis in patients with malignant melanoma.
Kärnell R; von Schoultz E; Hansson LO; Nilsson B; Arstrand K; Kågedal B
Melanoma Res; 1997 Oct; 7(5):393-9. PubMed ID: 9429222
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of melanin-related metabolites as markers of melanoma progression.
Horikoshi T; Ito S; Wakamatsu K; Onodera H; Eguchi H
Cancer; 1994 Feb; 73(3):629-36. PubMed ID: 8299084
[TBL] [Abstract][Full Text] [Related]
10. [Comparative studies between excretion of 5-S-cysteinyldopa and indole melanogens in urine].
Beyer C; Fiedler H; Wohlrab W; Wozniak KD
Dermatol Monatsschr; 1986; 172(9):541-4. PubMed ID: 3098590
[No Abstract] [Full Text] [Related]
11. Measurement of eumelanin precursor metabolites in the urine as a new marker for melanoma metastases.
Yamada K; Walsh N; Hara H; Jimbow K; Chen H; Ito S
Arch Dermatol; 1992 Apr; 128(4):491-4. PubMed ID: 1580656
[TBL] [Abstract][Full Text] [Related]
12. 5-S-cysteinyldopa in the urine of melanoma patients.
Agrup G; Agrup P; Andersson T; Falck B; Hansson JA; Jacobsson S; Rorsman H; Rosengren E; Rosengren AM
Acta Derm Venereol; 1977; 57(2):113-6. PubMed ID: 71802
[TBL] [Abstract][Full Text] [Related]
13. [Definitive diagnosis of early malignant melanoma lesions by the quantitative analysis of 5-S-cysteinyldopa in the tissue and touch fluorescence method].
Kanematsu S; Morishima T
Nihon Hifuka Gakkai Zasshi; 1989 Jun; 99(7):783-91. PubMed ID: 2511360
[TBL] [Abstract][Full Text] [Related]
14. [5-S-cysteinyldopa determination in the urine. Its value for monitoring in melanoma patients].
Paul E; Graef V; Ruppel R; Hellwich M
Z Hautkr; 1983 Feb; 58(4):262-5. PubMed ID: 6405551
[TBL] [Abstract][Full Text] [Related]
15. Determination of 5-S-cysteinyldopa in plasma and urine using a fully automated solid-phase extraction--high-performance liquid chromatographic method for an improvement of specificity and sensitivity of this prognostic marker of malignant melanoma.
Hartleb J; Damm Y; Arndt R; Christophers E; Stockfleth E
J Chromatogr B Biomed Sci Appl; 1999 Apr; 727(1-2):31-42. PubMed ID: 10360420
[TBL] [Abstract][Full Text] [Related]
16. Detection and quantitation of 5-S-cysteinyldopa in melanotic and amelanotic melanoma in comparison with nonpigment cell tumors and it's urinary excretion.
Mojamdar M; Ichihashi M; Mishima Y
J Dermatol; 1979 Dec; 6(6):379-82. PubMed ID: 120380
[No Abstract] [Full Text] [Related]
17. The value of cysteinyldopa in the follow-up of disseminated malignant melanoma.
Kärnell R; Kågedal B; Lindholm C; Nilsson B; Arstrand K; Ringborg U
Melanoma Res; 2000 Aug; 10(4):363-9. PubMed ID: 10985671
[TBL] [Abstract][Full Text] [Related]
18. [Urinary 5-S-cysteinyldopa in malignant melanoma subjects-with special reference to melanoma stages and dopa loading test (author's transl)].
Ichihasi M; Mojamdar M; Mishima Y
Nihon Hifuka Gakkai Zasshi; 1981 Sep; 91(10):1045-9. PubMed ID: 6798247
[No Abstract] [Full Text] [Related]
19. The urinary melanogen cysteinyldopa in melanoma and in suntanning: Australian experience.
Nixon PF
Aust N Z J Surg; 1978 Feb; 48(1):17-21. PubMed ID: 276342
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of serum 5-S-cysteinyldopa for monitoring human metastatic melanoma during immunochemotherapy.
Wimmer I; Meyer JC; Seifert B; Dummer R; Flace A; Burg G
Cancer Res; 1997 Nov; 57(22):5073-6. PubMed ID: 9371505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]